Novel research presented on KMA and LMA at IMS Annual Meeting in Toronto

Posted On: 22 Sep 2025


HaemaLogiX was pleased to attend the prestigious International Myeloma Society (IMS) Annual Meeting & Exposition, held last week from 14 – 17 September, 2025 in Toronto, Canada. This event is the pre-eminent global gathering of the myeloma scientific and research community, bringing together experts from around the world to share the latest advances in myeloma biology, treatment, and patient care.


At this important forum, HaemaLogiX was proud to present a poster titled:


"Novel therapeutic targets Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are expressed on malignant plasma cells from patients with plasma cell dyscrasias but not on normal plasma cells."


The research highlighted several key findings:

  1. KMA and LMA are present on bone marrow plasma cells in the majority of cases of plasma cell dyscrasias of all types and represent a potentially valuable target for immunotherapy
  2. In myeloma patients treated with standard of care therapies both KMA and LMA expression were increased on malignant plasma cells compared to BCMA, suggesting that our immunotherapies would also be effective in patients who don’t respond to myeloma treatments  
  3. Targeting KMA or LMA may leave alternative isotype plasma cells intact and reduce infectious complications and retain vaccine responsiveness after immunotherapy


This research underscores the potential of HaemaLogiX’s innovative immunotherapies, which are designed to specifically target KMA or LMA on the surface of malignant plasma cells, effectively directing the immune system to destroy these cancerous cells while minimising harm to normal plasma cells.


Dr Rosanne Dunn, CSO and Executive Director at HaemaLogiX, commented on the significance of the presentation:


“We were delighted to present this important research at the International Myeloma Society (IMS) Annual Meeting & Exposition, an important global forum where experts unite to share the latest advances in myeloma biology, treatment and patient care. Our poster highlighted findings that Kappa and Lambda Myeloma Antigens are consistently expressed on malignant plasma cells across a range of plasma cell dyscrasias, but not on normal plasma cells. This highlights their potential as highly specific targets for immunotherapy - offering a promising pathway to treat disease while preserving normal immune function.”


A copy of the poster presentation is available here: View poster